AddedRisk Factors
Maintaining effective internal control and disclosure controls and procedures requires ongoing attention and resources. We continue to seek improvements to enhance our control environment and to strengthen our internal controls to provide reasonable assurance that our financial statements continue to be fairly stated in all material respects.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedRisk Factors
In addition, the BIOSECURE Act was signed into law in December 2025 as part of the National Defense Authorization Act restricting U.S. federal contracts and funding for companies using biotech equipment or services from "biotechnology companies of concern" ("BCCs"), to curb national security risks. A phased rollout includes publishing lists of BCCs, issuing guidance, and revising Federal Acquisition Regulations with full prohibitions taking effect over a period of years. Compliance with this law will require us to perform additional supply chain due diligence and potentially change supplier sources if we wish to do business with the U.S. government such as the Veterans Administration. We cannot predict what actions may ultimately be taken with respect to trade relations between the United States and China or other countries, what products and services may be subject to such actions or what actions may be taken by the other countries in retaliation.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RemovedRisk Factors
•compliance risks associated with the General Data Protection Regulation (the “GDPR”) (including as it applies in the UK by virtue of the Data Protection Act 2018), enacted to protect the privacy of all individuals in the EU and the UK, and which places certain restrictions on the export of personally identifiable data outside of the EU or the UK, as applicable;
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
We have recently experienced significant changes in our executive leadership, for example the March 2023 resignation of Douglas Devine as Chief Operating Officer and the August 2024 resignation of Brice Bobzien as Chief Financial Officer and appointment of Daniel Wilson as Chief Financial Officer, and we may experience further changes in executive leadership in the future.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
Healthcare laws and regulations, and interpretations of the same, change frequently and may change significantly in the future. We may not be able to adapt our operations to address every new regulation or interpretation, and new regulations or interpretations may adversely affect our business. We also cannot assure that a review of our business by courts or regulatory authorities would not result in a determination that adversely affects our revenue and operating results.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
We previously identified material weaknesses in our internal control over financial reporting. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim consolidated financial statements will not be prevented or detected on a timely basis. As previously disclosed, in preparing our consolidated financial statements as of and for the years ended December 31, 2021 and 2020, our management concluded that our disclosure controls and procedures and our internal control over financial reporting were not effective at the reasonable assurance level due to a failure to maintain a sufficient number of professionals with an appropriate level of accounting and internal control knowledge, training, and experience to timely and accurately analyze, record, and disclose accounting matters. This material weakness contributed to additional material weaknesses, which have been previously disclosed and remediated. In aggregate, these material weaknesses (including the previously remediated material weaknesses) contributed to the misstatement of our revenues, revenue reserves, bad debt expense, property and equipment, research and development expense, and related financial disclosures, and in the revision of our consolidated financial statements for the years ended December 31, 2017, December 31, 2018, and each interim period therein as well as the quarters ended March 31, 2019, June 30, 2019, and September 30, 2019. Additionally, this material weakness could result in a misstatement of account balances or disclosures that would result in a material misstatement to the annual or interim consolidated financial statements that would not be prevented or detected.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
To address this material weakness, we took actions designed to improve our internal control over financial reporting and remediate the control deficiencies that led to the material weakness, including hiring additional accounting and finance personnel with an appropriate level of expertise, providing for additional management oversight over financial reporting including through the establishment of a SOX Steering Committee within our internal audit function, and implementing new controls and processes. As of the year ended December 31, 2022, we concluded that our remediation efforts had been successful and that the previously identified material weakness in internal control over financial reporting had been remediated. However, while the material weakness has been remediated, we continue to seek improvements to enhance our control environment and to strengthen our internal controls to provide reasonable assurance that our financial statements continue to be fairly stated in all material respects.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
In addition, legislation has been introduced in Congress to limit certain U.S. biotechnology companies from using equipment or services produced or provided by select Chinese biotechnology companies, including those affiliated with the manufacture of certain components of our Zio Monitor System, and others in Congress have advocated for the use of existing executive branch authorities to limit those Chinese service providers’ ability to engage in business in the U.S. We cannot predict what actions may ultimately be taken with respect to trade relations between the United States and China or other countries, what products and services may be subject to such actions or what actions may be taken by the other countries in retaliation.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RewordedRisk Factors
Both foreign and U.S. legislators and regulators may make legal and regulatory changes, or interpret and apply existing laws, in ways that require us to incur substantial costs, expose us to unanticipated civil or criminal liability, or cause us to change our business practices.As the regulatory guidance and enforcement landscape in relation to data transfers continue to develop, we could suffer additional costs, complaints and/or regulatory investigations or fines; we may have to stop using certain tools and vendors and make other operational changes; and/or it could adversely affect our business, financial condition, results of operations and prospects. practices.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
As part of this dialogue we agreed to make two 510(k) submissions relating to the Zio AT, and on On October 21, 2024, we were granted FDA clearance for one 510(k) encompassing design updates that had previously been documented through letters to file and on October 30, 2024 we were granted FDA clearance on a second 510(k) submission related to design modifications and labeling updates for the Zio AT device. file.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
As part of this dialogue we agreed to make two 510(k) submissions relating to the Zio AT, and on October 21, 2024, we were granted FDA clearance for one 510(k) encompassing design updates that had previously been documented through letters to file and on On October 30, 2024 we were granted FDA clearance on a second 510(k) submission related to design modifications and labeling updates for the Zio AT device. AT.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
Both foreign and U.S. legislators and regulators may make legal and regulatory changes, or interpret and apply existing laws, in ways that require us to incur substantial costs, expose us to unanticipated civil or criminal liability, or cause us to change our business practices.As As the regulatory guidance and enforcement landscape in relation to data transfers continue to develop, we could suffer additional costs, complaints and/or regulatory investigations or fines; we may have to stop using certain tools and vendors and make other operational changes; and/or it could adversely affect our business, financial condition, results of operations and prospects.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
For example, a regulator or other third party could assert that the Zio AT System cannot support MCT services, which Any such assertion could jeopardize our ability to obtain clearances with indications and labeling that provide for the scope we planned, and our ability to submit claims for reimbursement for services utilizing our Zio AT System and may require us to evaluate whether we have received any overpayments that must be reported and returned to third-party payors.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
Failure to maintain full compliance with the requirements of FDA's QMSR, the Quality System Regulation (“QSR”), also known as 21 CFR Part 820, EU Standards (presently MDR, the Medical Devices Regulations (“EU MDR”)), UK Medical Device Regulations (“UK MDR”), MDR, the Japanese medical device Quality Management System (“Japanese QMS”) QMS and the SMDO Swiss MedDO could result in similar disruptions in these markets.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
The success of this plan our efforts to evolve our revenue cycle management function depends on the ability of our ability to complete the integration of these service providers in a to deliver timely manner and accurate services that will continue to support our business as we scale our operations to facilitate growth opportunities, without adversely affecting current revenues and accounts receivable.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
If we do not implement the necessary quality measures to manage cybersecurity and minimize or avoid risks of a potential cyber-attack that impacts our devices and services, services in a way that regulators deem satisfactory, this could impact our product applications and in addition we could be subject to a range of FDA enforcement action, action or investigation by other regulatory agencies or enforcement bodies including DOJ, and such a situation could trigger the need for a recall, a hold on the distribution of our products, or require other corrective actions to our products.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
An increase in the reporting of events associated with the use of our products and services from us or others and any delays to the filing of reports may increase regulator and public scrutiny, especially given that these reports are typically publicly available information in most jurisdictions, including the United States, which could harm our business.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
Other foreign laws, such as the GDPR, GDPR and Swiss data protection laws, impose strict requirements for processing and cross-border transfers of personal data. data outside of the EU, UK or Switzerland to a “third country,” including the United States, unless particular compliance mechanisms are implemented.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
As we are already subject to an FDA warning letter associated with our Cypress facility, and in light of the 2024 inspection results, if If we are unable to successfully execute and maintain follow-up actions consistent with our commitments to FDA, or if FDA determines that our follow-up commitments are insufficient or are were not completed with sufficient promptness, we may face a greater risk of potential escalation, which could involve issuance of additional warning letters, or there is a possibility that FDA could initiate consent decree discussions.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our exploration of the sleep apnea screening and diagnostics market is in the early evaluation stages, and although we are devoting time and resources to this evaluation, we We do not anticipate meaningful revenue from any such opportunities to expand into the sleep apnea screening and diagnostics market for the foreseeable future.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
These activities are complex and time-consuming and can involve delays or additional and unforeseen expenses.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
As a result, we expect to may continue to incur operating losses in the future.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
The option counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to our common stock and/or purchasing or selling our common stock or other securities of ours in secondary market transactions at any point prior to the maturity of the 2029 Notes (and are likely to do so during any observation period related to a conversion of 2029 Notes or following any redemption or repurchase of 2029 Notes by us, in each case, if we elect to unwind a corresponding portion of the 2029 Capped Calls in connection with such conversion or such redemption or repurchase).
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
2 Excludes third-party attorneys' fees and expenses associated with patent litigation brought against the Company by Welch Allyn, Inc. and Bardy Diagnostics, Inc., subsidiaries of Baxter International, Inc.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
Impairment charges consist of amounts recorded to write down the carrying value of long-lived assets to fair value.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
On July 4, 2025, the United States enacted tax reform legislation commonly referred to as the One Big Beautiful Bill Act (“OBBBA”). Included in this legislation are provisions that allow for the immediate expensing of domestic U.S. research and development expenses, immediate expensing of certain capital expenditures, and other changes to the U.S. taxation of profits derived from foreign operations. The provisions of the OBBBA did not have a material impact on our Consolidated Financial Statements for the year ended December 31, 2025.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
We believe that our current cash, cash equivalents, and marketable securities balances, together with income to be derived from the sales of our iRhythm Services, will be sufficient to meet our liquidity requirements for at least the next 12 months.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
On January 12, 2026, we implemented the Holding Company Transaction. The Holding Company Transaction constituted a Merger Event as defined under the Indenture. The Holding Company Transaction did not constitute a Fundamental Change or a Make-Whole Fundamental Change as defined under the Indenture. As a result of the Holding Company Transaction, pursuant to Section 4.01(f) of the Indenture, holders may convert their 2029 Notes at any time up through March 4, 2026, the thirty-fifth trading day after the effective date of the Holding Company Transaction. As of the filing date of our annual report on Form 10-K, there have been no conversions.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
On January 12, 2026, in connection with the Holding Company Transaction, we entered into a supplemental indenture to the Indenture (the “First Supplemental Indenture”) in order to (a)(i) provide that the right to convert each $1,000 principal amount of 2029 Notes into shares of iRhythm Technologies common stock was changed to a right to convert such principal amount of 2029 Notes into shares of our common stock; (ii) iRhythm Technologies shall continue to have the right to determine the form of consideration to be paid or delivered, as the case may be, upon conversion of the 2029 Notes; (iii) any amount payable in cash upon conversion of the 2029 Notes in accordance with the Indenture shall continue to be payable in cash; (iv) any shares of common stock of iRhythm Technologies that iRhythm Technologies would have been required to deliver upon conversion shall instead be deliverable in shares of our common stock; and (v) the Daily VWAP (as defined in the Indenture) shall be calculated based on the value of a share of our common stock; and (b) provide for the full and unconditional guarantee by us of the obligations of iRhythm Technologies under the 2029 Notes and the Indenture.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
As of December 31, 2025, we held $20.4 million of contingent consideration liabilities related to development milestones from the acquisition of licensed technologies from BioIS. In June 2025, BioIS achieved the first of two regulatory milestones. As of December 31, 2025, BioIS and the Company are in the process of completing all required contractual conditions to cancel $10.0 million in Milestone Notes plus accrued and unpaid interest.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
In connection with the Holding Company Transaction, on January 12, 2026, we, as guarantor, iRhythm Technologies, and U.S. Bank Trust Company, National Association, entered into the First Supplemental Indenture. As of December 31, 2025, there was $661.3 million aggregate principal amount of issued and outstanding 2029 Notes of iRhythm Technologies that, as of January 12, 2026, are fully and unconditionally guaranteed by us. Accordingly, pursuant to Rule 3-10 of Regulation S-X, separate consolidated financial statements of iRhythm Technologies have not been presented. As permitted under Rule 13-01(a)(4)(vi) of Regulation S-X, we have excluded summarized financial information for iRhythm Technologies because the assets, liabilities and results of operations of iRhythm Technologies are not materially different than the corresponding amounts in our Consolidated Financial Statements.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RemovedMD&A
In October 2018, we entered into the Third Amended and Restated Loan and Security Agreement (“SVB Loan Agreement”) with Silicon Valley Bank (“SVB”). Under the SVB Loan Agreement, we had borrowed $35.0 million and had made repayments through March 2022, at which time the outstanding balance was $18.5 million.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
On March 28, 2022, we entered into a Second Amendment (the “2022 Amendment”) to our SVB Loan Agreement which provided for a term loans facility in the aggregate principal amount of up to $75.0 million (the “2022 Term Loans”), of which $35.0 million was borrowed at closing and a portion of the proceeds was used to pay in full the outstanding balance of $18.5 million under the SVB Loan Agreement. The remaining $40.0 million of 2022 Term Loans was available to be borrowed from time to time at our option, in increments of at least $10.0 million, through December 31, 2023. The 2022 Amendment also amended the terms of the revolving credit line under the SVB Loan Agreement, which provided for an aggregate principal amount of $25.0 million.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RewordedMD&A
The increase decrease was attributable to higher market lower interest rates earned from our cash, cash equivalents and marketable securities, as well as an increase in the average on invested balances during the year ended December 31, 2024 balances, as compared to the year ended December 31, 2023, same period in 2024, offset by higher average invested balances in 2025, primarily as a result of the borrowing under the 2029 Notes in March 2024.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
The increase in cash used in investing activities was primarily attributable to a net decrease increase in the change in marketable securities of $59.3 $211.4 million, primarily from an increase in the purchases of $54.0 marketable securities of $347.9 million related to the purchase offset by an increase in maturities of strategic loan investments, and the acquisition marketable securities of in-process research and development from BioIS of $15.0 $136.5 million.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
On August 30, 2024, we entered into a Technology License Agreement (as amended, the “License Agreement”) with BioIS, pursuant to which (i) we will receive a perpetual fully paid up license to certain of BioIS’ intellectual property, technology and products for research, development and commercialization of potential next generation products and services in certain fields of use, including (x) an exclusive license to develop and commercialize pulse oximetry, accelerometry, and trending non-invasive blood pressure technologies for use within our ambulatory cardiac monitoring products and services, and (y) a limited, non-exclusive license to develop and commercialize products and services for use in unattended, home-based diagnostic testing and assessment of central and obstructive sleep apnea, and (ii) the parties iRhythm and BioIS agreed to negotiate in good faith a supply agreement for pulse oximetry hardware.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
The increase in research and development expenses during the twelve months year ended December 31, 2024 2025 was primarily due to higher headcount-related employee-related costs (including stock-based compensation), which include supporting ongoing FDA remediation and sustaining activities, product development consulting costs, and costs to support regulatory affairs, product development, and legal matters, and further development, enhancement enhancement, and functionality of our current and future product offerings.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
The increase in interest expense was during the year ended December 31, 2025, is primarily attributable to the $75.0 million Braidwell Term Loan Facility (as defined below) borrowed and repaid during the first quarter of 2024, as well as the $661.3 million 2029 Notes borrowed in March 2024.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
For discussion related to the results of operations and changes in financial condition for fiscal 2023 the year ended December 31, 2024 compared to fiscal 2022 the year ended December 31, 2023 refer to “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part II, Item 7 of our 2023 Annual Report on Form 10-K, 10-K for the year ended December 31, 2024, which was filed with the SEC on February 22, 2024. 20, 2025.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
Revenue increased by $99.2 $155.3 million, or 20%, 26%, to $747.1 million during the year ended December 31, 2025, as compared to $591.8 million during the year ended December 31, 2024, as compared to $492.7 million during the year ended December 31, 2023. 2024.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
Cost of revenue increased by $23.4 $35.6 million, or 15%, 19%, to $219.9 million during the year ended December 31, 2025, as compared to $184.3 million during the year ended December 31, 2024, as compared to $160.9 million during the year ended December 31, 2023. 2024.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
Research and development expenses increased by $11.2 $13.2 million, or 19%, 18%, to $84.6 million during the year ended December 31, 2025, as compared to $71.5 million during the year ended December 31, 2024, as compared to $60.2 million during the year ended December 31, 2023. 2024.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
Selling, general and administrative expenses increased by $32.9 $74.0 million, or 9%, 18%, to $492.6 million during the year ended December 31, 2025, as compared to $418.6 million during the year ended December 31, 2024, as compared to $385.6 million during the year ended December 31, 2023. 2024.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
Interest income increased decreased by $15.6 $0.4 million to $21.5 million during the year ended December 31, 2025, as compared to $21.9 million during the year ended December 31, 2024, as compared to $6.4 million during the year ended December 31, 2023. 2024.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
Selling, general and administrative expenses increased by $32.9 million, or 9%, to $418.6 We incurred $3.0 million of business transformation costs during the year ended December 31, 2024, 2025, as compared to $385.6 $11.1 million during for the year ended December 31, 2023. 2024.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
Quiet changesMD&A
The net proceeds from the offering, after deducting initial purchasers’ discounts and estimated costs directly related to the offering, were approximately $643.8 million.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
Quiet changesMD&A
The 2029 Capped Calls will cover, subject to anti-dilution adjustments substantially similar to those applicable to the 2029 Notes, the number of shares of our common stock that will initially underlie the 2029 Notes.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new